Rainbow Coral (RBCC) 10-K/A 11 Sep 15 2015 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2015	Jul. 13, 2015	Sep. 30, 2014
Document and Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Mar. 31, 2015
Entity Registrant Name	Rainbow Coral Corp.
Entity Central Index Key	1,499,790
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,015
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 434,832
Entity Units Outstanding		7,535,450
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2015	Mar. 31, 2014
CURRENT ASSETS
Cash and cash equivalents	$ 5,180	$ 65,373
Prepaid expenses	1,095	841
Inventory	1,139	5,249
Total current assets	7,414	71,463
Fixed assets net of accumulated depreciation of $2,795 and $7,615, respectively	3,914	6,282
TOTAL ASSETS	11,328	77,745
CURRENT LIABILITIES
Accounts payable and accrued expenses	$ 274,684	191,780
Advances payable		149,453
Related party advances payable	$ 165,214	131,505
Current portion of notes payable	13,734	2,843
Total current liabilities	453,632	475,581
Convertible notes payable, net of discount of $237,643 and $215,716, respectively	164,238	13,111
Notes payable	37,352	47,157
Accrued interest payable	14,127	11,201
TOTAL LIABILITIES	$ 669,349	$ 547,050
STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at March 31, 2015 and 2014, respectively
Common stock, $0.001 par value; 480,000,000 shares authorized; 342,106 and 228,521 shares issued and outstanding at March 31, 2015 and 2014, respectively	$ 342	$ 229
Additional paid-in capital	3,264,425	2,463,021
Accumulated deficit	(3,922,788)	(2,932,555)
Total stockholders' deficit	(658,021)	(469,305)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 11,328	$ 77,745

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($)	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED BALANCE SHEETS [Abstract]
Accumulated depreciation	$ 2,795	$ 7,615
Noncurrent convertible notes payable discount	$ 237,643	$ 215,716
Preferred Stock, par value per share	$ 0.001	$ 0.001
Preferred Stock, shares authorized	20,000,000	20,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value per share	$ 0.001	$ 0.001
Common Stock, shares authorized	480,000,000	480,000,000
Common Stock, shares issued	342,106	228,521
Common Stock, shares outstanding	342,106	228,521

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
REVENUE	$ 128,133	$ 113,009
COST OF GOODS SOLD	69,745	113,228
GROSS PROFIT	58,388	(219)
OPERATING EXPENSES
Expenses related to joint ventures and other business development agreements	80,000	85,000
General and administrative expenses	$ 564,387	557,031
Impairment of goodwill		27,868
LOSS FROM OPERATIONS	$ (585,999)	(670,118)
OTHER EXPENSE
Interest expense	(404,234)	(427,023)
NET LOSS	$ (990,233)	$ (1,097,141)
NET LOSS PER COMMON SHARE - Basic and diluted	$ (3.27)	$ (6.59)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and diluted	302,693	166,360

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
BALANCE at Mar. 31, 2013	$ (234,958)	$ 125	$ 1,600,331	$ (1,835,414)
BALANCE, SHARES at Mar. 31, 2013		125,200
Shares issued for conversion of notes payable	446,109	$ 104	446,005
Shares issued for conversion of notes payable, shares		103,321
Discount on issuance of convertible notes payable	416,685		$ 416,685
Net loss	(1,097,141)			$ (1,097,141)
BALANCE at Mar. 31, 2014	$ (469,305)	$ 229	$ 2,463,021	$ (2,932,555)
BALANCE, SHARES at Mar. 31, 2014	228,521	228,521
Shares issued for conversion of notes payable	$ 401,582	$ 113	401,469
Shares issued for conversion of notes payable, shares		113,585
Discount on issuance of convertible notes payable	399,935		$ 399,935
Net loss	(990,233)			$ (990,233)
BALANCE at Mar. 31, 2015	$ (658,021)	$ 342	$ 3,264,425	$ (3,922,788)
BALANCE, SHARES at Mar. 31, 2015	342,106	342,106

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOW FROM OPERATING ACTIVITIES:
Net loss	$ (990,233)	$ (1,097,141)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on convertible notes payable	378,008	398,067
Depreciation	$ 2,368	5,854
Impairment of goodwill		27,868
Impairment of inventory		14,500
Changes in operating assets and liabilities:
Inventory	$ 4,110	9,271
Prepaid expenses	(254)	(491)
Accounts payable and accrued liabilities	207,963	74,429
Accrued interest payable	26,228	35,825
NET CASH USED IN OPERATING ACTIVITIES	$ (371,810)	(531,818)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets		(6,708)
NET CASH USED IN INVESTING ACTIVITIES		(6,708)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from advances	$ 276,822	432,683
Proceeds from related party advances	$ 33,709	38,442
Repayments of related party advances		(1,818)
Proceeds from notes payable	$ 5,000	$ 50,000
Repayments of notes payable	(3,914)
NET CASH PROVIDED BY FINANCING ACTIVITIES	311,617	$ 519,307
NET DECREASE IN CASH	(60,193)	(19,219)
CASH, at the beginning of the period	65,373	84,592
CASH, at the end of the period	$ 5,180	$ 65,373
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for: Interest
Cash paid during the period for: Taxes
Noncash investing and financing activities:
Refinance of advances into convertible notes payable	$ 426,275	$ 416,685
Refinance of accounts payable into convertible notes payable	125,059
Beneficial conversion discount on convertible notes	399,935	$ 416,685
Conversion of convertible notes to common stock	$ 401,582	$ 446,109

Background Information

Background Information	12 Months Ended
	Mar. 31, 2015
Background Information [Abstract]
Background Information	Note 1. Background Information RAINBOW CORAL CORP. (the “Company”) was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest, and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company's coral farming activity. We believe that the world of bioresearch is a natural continuation of our core coral propagation business. Accordingly, on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets. The Company was incorporated in Florida on August 13, 2010. The Company's fiscal year end is March 31. On May 29, 2015, we reincorporated from Florida to Nevada. Each shareholder received one share in the Nevada company for each 100 480 20 0.001 All share and per share amounts have been retroactively restated in the accompanying financial statements and notes to financial statements to reflect this reverse stock split. Joint Ventures On March 13, 2012, the Company entered into a stock purchase agreement (“N3D Stock Purchase Agreement”) with Nano3D Biosciences, Inc. (“N3D”), a Texas corporation that has developed a unique concept in three dimensional cell research tools. Under the terms of the N3D Stock Purchase Agreement, the Company agreed to acquire 604 5 413.62 249,826 5,000 60,000 145 The Company discontinued payments to N3D in May 2012 because of their delay in reaching certain milestones in the commercialization process. The Company wrote off the investment in full due to the uncertainty about whether the carrying amount is recoverable. During the year ended March 31, 2015, the Company paid and expensed $ 60,000 On February 1, 2013, the Company entered into a joint venture agreement with TheraKine Ltd. (“TheraKine”) in order to explore potential business opportunities to exploit TheraKine's drug delivery technologies. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective, and more convenient than ever before. During the year ended March 31, 2015, the Company paid and expensed $ 20,000

Going Concern

Going Concern	12 Months Ended
	Mar. 31, 2015
Going Concern [Abstract]
Going Concern	Note 2. Going Concern For the fiscal year ended March 31, 2015, the Company had a net loss of $ 990,233 371,810 446,218 These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern. The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business. Management has plans to address the Company's financial situation as follows: In the near term, management plans to continue to focus on raising the funds necessary to implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raises doubts about the Company's ability to continue as a going concern. In the long term, management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company that will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to achieve adequate profitability and cash flows from operations to sustain its operations.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Significant Accounting Policies	Note 3. Significant Accounting Policies Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Cash and Cash Equivalents For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $ 5,180 65,373 Inventory Inventory consists of aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence. Fixed Assets Our fixed assets consist of vehicles and computer equipment, which are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes. Impairment of long-lived assets Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the year ended March 31, 2015. Revenue and cost recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances. Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products that have been sold. Advertising Costs The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $ 3,832 23,239 Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes Earnings (Loss) per Common Share The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share . The basic earnings (loss) per common share are calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Company's convertible debt is considered anti-dilutive due to the Company's net loss for the years ended March 31, 2015 and 2014. As a result, the Company did not have any potentially dilutive common shares for those periods. For the year ended March 31, 2015 and 2014, potentially issuable shares as a result of conversions of convertible notes payable have been excluded from the calculation. At March 31, 2015, the Company had 27,458,608 Financial Instruments The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value. Subsequent events The Company evaluated material events occurring between the end of our fiscal year, March 31, 2015, and through the date when the consolidated financial statements were available to be issued for disclosure consideration. Recently Issued Accounting Pronouncements Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Advances

Advances	12 Months Ended
	Mar. 31, 2015
Advances [Abstract]
Advances	Note 4. Advances During the year ended March 31, 2015, Vista View Ventures, Inc. advanced $ 276,822 426,275 0 149,453

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Mar. 31, 2015
Convertible Notes Payable [Abstract]
Convertible Notes Payable	Note 5. Convertible Notes Payable Convertible notes payable consist of the following as of March 31, 2015 and March 31, 2014: March 31, 2015 March 31, 2014 Convertible note payable, dated June 30, 2013 10 June 30, 2015 0.04 $ — $ 4,742 Convertible note payable, dated September 30, 2013 10 September 30, 2015 0.04 — 224,085 Convertible note payable, dated June 30, 2014 10 June 30, 2016 0.02 62,980 — Convertible note payable, dated September 30, 2014 10 September 30, 2016 0.01 80,133 — Convertible note payable, dated December 31, 2014 10 December 31, 2016 0.01 94,074 — Convertible note payable, dated December 31, 2014 10 December 31, 2016 0.02 125,059 — Convertible note payable, dated March 31, 2015 10 March 31, 2017 0.007 39,635 — Total convertible notes payable $ 401,881 $ 228,827 Less: discount on convertible notes payable (237,643 ) (215,716 ) Convertible notes payable, net of discount $ 164,238 $ 13,111 Convertible notes issued During the year ended March 31, 2015, the Company entered into convertible promissory notes with Vista View Ventures, Inc., which refinanced non-interest bearing advances. The convertible notes have the following terms: Date Issued Maturity Date Interest Conversion Amount of April 1, 2014 March 31, 2016 10 % $ 0.03 $ 149,453 June 30, 2014 June 30, 2016 10 % $ 0.02 62,980 September 30, 2014 September 30, 2016 10 % $ 0.01 80,133 December 31, 2014 December 31, 2016 10 % $ 0.01 94,074 December 31, 2014 December 31, 2016 10 % $ 0.02 125,059 March 31, 2015 March 31, 2017 10 % $ 0.007 39,635 Total $ 551,334 All principal along with accrued interest is payable on the maturity date. The Company evaluated the terms of the notes in accordance with ASC Topic No. 815 – 40, Derivatives and Hedging - Contracts in Entity's Own Stock 399,935 Conversions to common stock During the year ended March 31, 2015, the holder of the convertible note payable dated June 30, 2013 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $ 0.04 No Date Amount Converted Shares of Common Stock Issued August 20, 2014 $ 4,954 1,239 Total $ 4,954 1,239 During the year ended March 31, 2015, the holder of the convertible note payable dated September 30, 2013 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $ 0.04 No Date Amount Converted Shares of Common Stock Issued April 21, 2014 $ 80,000 20,000 May 14, 2014 40,000 10,000 May 23, 2014 40,000 10,000 June 14, 2014 40,000 10,000 June 18, 2014 38,368 9,592 Total $ 238,368 59,592 During the year ended March 31, 2015, the holder of the Convertible Note Payable dated April 1, 2014 elected to convert principal and accrued interest in the amounts shown below into shares of common stock at a rate of $ 0.03 No Date Amount Converted Shares of Common Stock Issued October 8, 2014 $ 42,000 14,000 October 9, 2014 42,000 14,000 October 22, 2014 42,000 14,000 January 15, 2015 32,260 10,754 Total $ 158,260 52,754 In connection with the 1 100 27,458,608 99 no 4.99

Long Term Notes payable

Long Term Notes payable	12 Months Ended
	Mar. 31, 2015
Notes payable [Abstract]
Notes payable	Note 6. Long Term Notes Payable On December 30, 2013, the Company entered into a promissory note for $ 50,000 5 January 1, 2015 4 48,150 50,000 During the year ended March 31, 2015, the Company entered into a promissory note for $ 5,000 5 twenty-six monthly October 2014 2,936

Debt Payment Obligation

Debt Payment Obligation	12 Months Ended
	Mar. 31, 2015
Debt Payment Obligation [Abstract]
Debt Payment Obligations	Note 7. Debt Payment Obligations The principal due on our convertible notes payable and convertible notes payable is as follows: For the periods ending March 31, 2016 $ 13,734 2017 415,640 2018 13,229 2019 10,364 2020 — Total payments $ 452,967

Related Party Transactions

Related Party Transactions	12 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 8. Related Party Transactions During the years ended March 31, 2015 and 2014, Mr. Foxwell, the president of Father Fish, advanced $ 33,709 38,442 165,214 131,505

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Mar. 31, 2015
Stockholders
Stockholders' Deficit	Note 9. Stockholders' Equity On May 29, 2015, the Company reincorporated from Florida to Nevada. The Company's board of directors and majority shareholder consented to the reincorporation. Each of our shareholders on the record date received one share of the Nevada Company's common stock for each 100 shares of common stock they own in the Florida company. The information contained herein gives retroactive effect to the stock split for all periods presented. Fractional shares were rounded up to the next whole share, and each shareholder received at least five shares. Following the reincorporation, the Company is authorized to issue 480 20 0.001 At March 31, 2015, the Company had 27,458,608 0.007 0.02 0.01 During year ended March 31, 2015, the holders of our convertible notes elected to convert principal and interest of $ 401,582 113,585

Commitments

Commitments	12 Months Ended
	Mar. 31, 2015
Commitments [Abstract]
Commitments	Note 10. Commitments The Company has an arrangement with a third party whereby the third party provides the Company with office space, legal services, accounting services, fundraising and management services. During the year ended March 31, 2015, the Company incurred $ 200,383 172,246

Business Segments

Business Segments	12 Months Ended
	Mar. 31, 2015
Business Segments [Abstract]
Business Segments	Note 11. Business Segments The Company has two reportable operating segments: (1) aquarium and aquarium supplies and (2) medical technology. These reportable segments are financed and managed separately due to differences in their products and overall business plan. The only segment that generates revenue is aquarium and aquarium supplies. Management evaluates and monitors performance of this segment primarily through, among other measures, gross profit. The medical technology segment is in the development stage and not begun to generate revenue. The results of operations and financial position of the two reportable operating segments and corporate were as follows: Results of Operations: Year ended March 31, 2015 2014 REVENUE Aquarium and aquarium supplies $ 128,133 $ 113,009 Medical technology — — Corporate — — $ 128,133 $ 113,009 GROSS PROFIT (LOSS) Aquarium and aquarium supplies $ 58,388 $ (219 ) Medical technology — — Corporate — — $ 58,388 (219 ) OPERATING EXPENSES Aquarium and aquarium supplies $ 103,091 $ 144,788 Medical technology 80,000 85,000 Corporate 461,296 440,111 $ 644,387 $ 669,899 Corporate operating expense includes general and administrative costs not allocated to operating segments. March 31, 2015 March 31, 2014 TOTAL ASSETS Aquarium and aquarium supplies $ 6,800 $ 24,756 Medical technology — — Corporate 4,528 52,989 $ 11,328 $ 77,745

Income Taxes

Income Taxes	12 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Income Taxes	Note 12. Income Taxes There is no current or deferred income tax expense or benefit for the period ended March 31, 2015. The provision for income taxes is different from that which would be obtained by applying the statutory federal income tax rate to income before income taxes. The items causing this difference for the periods ended March 31, 2015 and 2014 are as follows. 2015 2014 Tax benefit at U.S. statutory rate $ 337,000 $ 370,000 Amortization of discount on convertible notes payable (136,000 ) (160,000 ) Changes in valuation allowance (201,000 ) (210,000 ) $ — $ —

Subsequent Events

Subsequent Events	12 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events On May 29, 2015 Nevada On June 1, 2015 125,059 130,267 6,513,344 On June 6, 2015 62,980 13,600 680,000

Significant Accounting Polici20

Significant Accounting Policies (Policy)	12 Months Ended
	Mar. 31, 2015
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $ 5,180 65,373
Inventory	Inventory Inventory consists of aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence.
Fixed Assets	Fixed Assets Our fixed assets consist of vehicles and computer equipment, which are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred. Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
Impairment of Long-Lived Assets	Impairment of long-lived assets Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the year ended March 31, 2015.
Revenue and Cost Recognition	Revenue and cost recognition The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances. Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products that have been sold.
Advertising Costs	Advertising Costs The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $ 3,832 23,239
Income Taxes	Income Taxes The Company accounts for income taxes under ASC 740 Income Taxes
Earnings (Loss) per Common Share	Earnings (Loss) per Common Share The Company computes basic and diluted earnings per common share amounts in accordance with ASC Topic 260, Earnings per Share . The basic earnings (loss) per common share are calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. There are no dilutive shares outstanding for any periods reported. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Company's convertible debt is considered anti-dilutive due to the Company's net loss for the years ended March 31, 2015 and 2014. As a result, the Company did not have any potentially dilutive common shares for those periods. For the year ended March 31, 2015 and 2014, potentially issuable shares as a result of conversions of convertible notes payable have been excluded from the calculation. At March 31, 2015, the Company had 27,458,608
Financial Instruments	Financial Instruments The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization. Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means. Level 3 - Inputs that are both significant to the fair value measurement and unobservable. Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of March 31, 2015. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
Subsequent events	Subsequent events The Company evaluated material events occurring between the end of our fiscal year, March 31, 2015, and through the date when the consolidated financial statements were available to be issued for disclosure consideration.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Mar. 31, 2015
Convertible Notes Payable [Abstract]
Schedule of Convertible Notes Payable	March 31, 2015 March 31, 2014 Convertible note payable, dated June 30, 2013 10 June 30, 2015 0.04 $ — $ 4,742 Convertible note payable, dated September 30, 2013 10 September 30, 2015 0.04 — 224,085 Convertible note payable, dated June 30, 2014 10 June 30, 2016 0.02 62,980 — Convertible note payable, dated September 30, 2014 10 September 30, 2016 0.01 80,133 — Convertible note payable, dated December 31, 2014 10 December 31, 2016 0.01 94,074 — Convertible note payable, dated December 31, 2014 10 December 31, 2016 0.02 125,059 — Convertible note payable, dated March 31, 2015 10 March 31, 2017 0.007 39,635 — Total convertible notes payable $ 401,881 $ 228,827 Less: discount on convertible notes payable (237,643 ) (215,716 ) Convertible notes payable, net of discount $ 164,238 $ 13,111
Schedule of Convertible Notes Issued	Date Issued Maturity Date Interest Conversion Amount of April 1, 2014 March 31, 2016 10 % $ 0.03 $ 149,453 June 30, 2014 June 30, 2016 10 % $ 0.02 62,980 September 30, 2014 September 30, 2016 10 % $ 0.01 80,133 December 31, 2014 December 31, 2016 10 % $ 0.01 94,074 December 31, 2014 December 31, 2016 10 % $ 0.02 125,059 March 31, 2015 March 31, 2017 10 % $ 0.007 39,635 Total $ 551,334
Schedule of Conversions To Common Stock	Date Amount Converted Shares of Common Stock Issued August 20, 2014 $ 4,954 1,239 Total $ 4,954 1,239 Date Amount Converted Shares of Common Stock Issued April 21, 2014 $ 80,000 20,000 May 14, 2014 40,000 10,000 May 23, 2014 40,000 10,000 June 14, 2014 40,000 10,000 June 18, 2014 38,368 9,592 Total $ 238,368 59,592 Date Amount Converted Shares of Common Stock Issued October 8, 2014 $ 42,000 14,000 October 9, 2014 42,000 14,000 October 22, 2014 42,000 14,000 January 15, 2015 32,260 10,754 Total $ 158,260 52,754

Debt Payment Obligations (Table

Debt Payment Obligations (Tables)	12 Months Ended
	Mar. 31, 2015
Debt Payment Obligation [Abstract]
Debt Payment Obligations	For the periods ending March 31, 2016 $ 13,734 2017 415,640 2018 13,229 2019 10,364 2020 — Total payments $ 452,967

Business Segments (Tables)

Business Segments (Tables)	12 Months Ended
	Mar. 31, 2015
Business Segments [Abstract]
Schedule of Results of Operations by Reporting Segment	Results of Operations: Year ended March 31, 2015 2014 REVENUE Aquarium and aquarium supplies $ 128,133 $ 113,009 Medical technology — — Corporate — — $ 128,133 $ 113,009 GROSS PROFIT (LOSS) Aquarium and aquarium supplies $ 58,388 $ (219 ) Medical technology — — Corporate — — $ 58,388 (219 ) OPERATING EXPENSES Aquarium and aquarium supplies $ 103,091 $ 144,788 Medical technology 80,000 85,000 Corporate 461,296 440,111 $ 644,387 $ 669,899 Corporate operating expense includes general and administrative costs not allocated to operating segments. March 31, 2015 March 31, 2014 TOTAL ASSETS Aquarium and aquarium supplies $ 6,800 $ 24,756 Medical technology — — Corporate 4,528 52,989 $ 11,328 $ 77,745

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2015
Income Taxes [Abstract]
Schedule of Income Tax Rate Reconciliation	2015 2014 Tax benefit at U.S. statutory rate $ 337,000 $ 370,000 Amortization of discount on convertible notes payable (136,000 ) (160,000 ) Changes in valuation allowance (201,000 ) (210,000 ) $ — $ —

Background Information (Details

Background Information (Details)	May. 29, 2015$ / sharesshares	Mar. 31, 2012USD ($)$ / sharesshares	Mar. 31, 2015USD ($)$ / sharesshares	Mar. 31, 2014USD ($)$ / sharesshares
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares			$ 0.001	$ 0.001
Common Stock, shares authorized			480,000,000	480,000,000
Preferred Stock, par value per share | $ / shares			$ 0.001	$ 0.001
Preferred Stock, shares authorized			20,000,000	20,000,000
Related Party Transaction [Line Items]
Expenses related to joint ventures and other business development agreements | $			$ 80,000	$ 85,000
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, par value per share | $ / shares	$ 0.001
Common Stock, shares authorized	480,000,000
Preferred Stock, par value per share | $ / shares	$ 0.001
Preferred Stock, shares authorized	20,000,000
Reverse stock split ratio	0.01
Reincorporation, state	Nevada
Reincorporation, date	May 29, 2015
Nano3D Biosciences, Inc. ("N3D") [Member]
Related Party Transaction [Line Items]
Shares acquired of joint venture's common stock		145
Payments to joint venture | $		$ 60,000
Expenses related to joint ventures and other business development agreements | $			60,000
Nano3D Biosciences, Inc. ("N3D") [Member] | Scenario, Plan [Member]
Related Party Transaction [Line Items]
Shares acquired of joint venture's common stock		604
Percentage of outstanding stock acquired		5.00%
Common stock, price per share | $ / shares		$ 413.62
Payments to joint venture | $		$ 249,826
Weekly payments to joint venture | $		$ 5,000
TheraKine Ltd. ("TheraKine") [Member]
Related Party Transaction [Line Items]
Expenses related to joint ventures and other business development agreements | $			$ 20,000

Going Concern (Details)

Going Concern (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Going Concern [Abstract]
Net loss	$ 990,233	$ 1,097,141
Net cash used in operating activities	371,810	$ 531,818
Negative working capital	$ 446,218

Significant Accounting Polici27

Significant Accounting Policies (Details)	12 Months Ended
	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)	Mar. 31, 2013USD ($)
Significant Accounting Policies [Abstract]
Cash and cash equivalents	$ 5,180	$ 65,373	$ 84,592
Advertising costs	$ 3,832	$ 23,239
Potentially issuable shares upon the conversion of convertible notes payable and interest | shares	27,458,608
Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	3 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated Useful Lives	5 years

Advances (Details)

Advances (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Advances [Abstract]
Proceeds from advances	$ 276,822	$ 432,683
Refinance of advances into convertible notes payable	$ 426,275	416,685
Advances payable		$ 149,453

Convertible Notes Payable (Sche

Convertible Notes Payable (Schedule of Convertible Notes Payable) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Convertible notes payable, net of discount	$ 164,238	$ 13,111
Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	401,881	228,827
Less: discount on convertible notes payable	(237,643)	(215,716)
Convertible notes payable, net of discount	$ 164,238	13,111
Convertible Note Payable Dated June 30, 2013 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable		4,742
Debt instrument, issuance date	Jun. 30, 2013
Debt instrument, maturity date	Jun. 30, 2015
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.04
Convertible Note Payable Dated September 30, 2013 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable		$ 224,085
Debt instrument, issuance date	Sep. 30, 2013
Debt instrument, maturity date	Sep. 30, 2015
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.04
Convertible Note Payable Dated April 1, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Apr. 1, 2014
Debt instrument, maturity date	Mar. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.03
Convertible Note Payable Dated June 30, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 62,980
Debt instrument, issuance date	Jun. 30, 2014
Debt instrument, maturity date	Jun. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Convertible Note Payable Dated September 20, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 80,133
Debt instrument, issuance date	Sep. 30, 2014
Debt instrument, maturity date	Sep. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01
Convertible Note Payable Dated December 31, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 94,074
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01
Convertible Note Payable Dated December 31, 2014, Two [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 125,059
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Convertible Note Payable Dated March 31, 2015 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Total convertible notes payable	$ 39,635
Debt instrument, issuance date	Mar. 31, 2015
Debt instrument, maturity date	Mar. 31, 2017
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.007

Convertible Notes Payable (Sc30

Convertible Notes Payable (Schedule of Convertible Notes Issued) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Debt Instrument [Line Items]
Beneficial conversion discount on convertible notes	$ 399,935	$ 416,685
Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 551,334
Convertible Note Payable Dated April 1, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Apr. 1, 2014
Debt instrument, maturity date	Mar. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.03
Debt instrument, face amount	$ 149,453
Convertible Note Payable Dated June 30, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Jun. 30, 2014
Debt instrument, maturity date	Jun. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Debt instrument, face amount	$ 62,980
Convertible Note Payable Dated September 20, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Sep. 30, 2014
Debt instrument, maturity date	Sep. 30, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01
Debt instrument, face amount	$ 80,133
Convertible Note Payable Dated December 31, 2014 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.01
Debt instrument, face amount	$ 94,074
Convertible Note Payable Dated December 31, 2014, Two [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Dec. 31, 2014
Debt instrument, maturity date	Dec. 31, 2016
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.02
Debt instrument, face amount	$ 125,059
Convertible Note Payable Dated March 31, 2015 [Member] | Refinance Non-Interest Bearing Advances [Member]
Debt Instrument [Line Items]
Debt instrument, issuance date	Mar. 31, 2015
Debt instrument, maturity date	Mar. 31, 2017
Debt instrument, interest rate	10.00%
Debt instrument, conversion price per share	$ 0.007
Debt instrument, face amount	$ 39,635

Convertible Notes Payable (Conv

Convertible Notes Payable (Conversions to Common Stock) (Details)	May. 29, 2015	Mar. 31, 2015USD ($)shares	Mar. 31, 2014USD ($)
Debt Conversion [Line Items]
Amount Converted | $		$ 401,582	$ 446,109
Shares of Common Stock Issued		113,585
Potentially issuable shares upon the conversion of convertible notes payable and interest		27,458,608
Maximum ownership percentage allowed after converting		4.99%
Percentage of the Company's total shares outstanding on an if-converted basis		99.00%
Convertible Note Payable Dated June 30, 2013 [Member]
Debt Conversion [Line Items]
Amount Converted | $		$ 4,954
Shares of Common Stock Issued		1,239
Convertible Note Payable Dated June 30, 2013 [Member] | Debt Conversion August 20, 2014 [Member]
Debt Conversion [Line Items]
Date		Aug. 20, 2014
Amount Converted | $		$ 4,954
Shares of Common Stock Issued		1,239
Convertible Note Payable Dated September 30, 2013 [Member]
Debt Conversion [Line Items]
Amount Converted | $		$ 238,368
Shares of Common Stock Issued		59,592
Convertible Note Payable Dated September 30, 2013 [Member] | Debt Conversion April 21, 2014 [Member]
Debt Conversion [Line Items]
Date		Apr. 21, 2014
Amount Converted | $		$ 80,000
Shares of Common Stock Issued		20,000
Convertible Note Payable Dated September 30, 2013 [Member] | Debt Conversion May 14, 2014 [Member]
Debt Conversion [Line Items]
Date		May 14, 2014
Amount Converted | $		$ 40,000
Shares of Common Stock Issued		10,000
Convertible Note Payable Dated September 30, 2013 [Member] | Debt Conversion May 23, 2014 [Member]
Debt Conversion [Line Items]
Date		May 23, 2014
Amount Converted | $		$ 40,000
Shares of Common Stock Issued		10,000
Convertible Note Payable Dated September 30, 2013 [Member] | Debt Conversion June 14, 2014 [Member]
Debt Conversion [Line Items]
Date		Jun. 14, 2014
Amount Converted | $		$ 40,000
Shares of Common Stock Issued		10,000
Convertible Note Payable Dated September 30, 2013 [Member] | Debt Conversion June 18, 2014 [Member]
Debt Conversion [Line Items]
Date		Jun. 18, 2014
Amount Converted | $		$ 38,368
Shares of Common Stock Issued		9,592
Convertible Note Payable Dated April 1, 2014 [Member]
Debt Conversion [Line Items]
Amount Converted | $		$ 158,260
Shares of Common Stock Issued		52,754
Convertible Note Payable Dated April 1, 2014 [Member] | Debt Conversion October 8, 2014 [Member]
Debt Conversion [Line Items]
Date		Oct. 8, 2014
Amount Converted | $		$ 42,000
Shares of Common Stock Issued		14,000
Convertible Note Payable Dated April 1, 2014 [Member] | Debt Conversion October 9, 2014 [Member]
Debt Conversion [Line Items]
Date		Oct. 9, 2014
Amount Converted | $		$ 42,000
Shares of Common Stock Issued		14,000
Convertible Note Payable Dated April 1, 2014 [Member] | Debt Conversion October 22, 2014 [Member]
Debt Conversion [Line Items]
Date		Oct. 22, 2014
Amount Converted | $		$ 42,000
Shares of Common Stock Issued		14,000
Convertible Note Payable Dated April 1, 2014 [Member] | Debt Conversion January 15, 2014 [Member]
Debt Conversion [Line Items]
Date		Jan. 15, 2015
Amount Converted | $		$ 32,260
Shares of Common Stock Issued		10,754
Subsequent Event [Member]
Debt Conversion [Line Items]
Reverse stock split ratio	0.01

Long Term Notes payable (Detail

Long Term Notes payable (Details) - Promissory Note [Member] - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Promissory Note, Dated December 30, 2013 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 50,000
Debt instrument, interest rate	5.00%
Debt instrument, installment payments start date	Jan. 1, 2015
Debt instrument, repayment term	4 years
Notes payable	$ 48,150	$ 50,000
Promissory Note, Issued During the Year Ended March 31, 2015 [Member]
Debt Instrument [Line Items]
Debt instrument, face amount	$ 5,000
Debt instrument, interest rate	5.00%
Debt instrument, frequency of payment	monthly
Debt instrument, installment payments start date	Oct. 1, 2014
Debt instrument, repayment term	26 months
Notes payable	$ 2,936

Debt Payment Obligations (Detai

Debt Payment Obligations (Details)	Mar. 31, 2015USD ($)
For the periods ending March 31,
2,016	$ 13,734
2,017	415,640
2,018	13,229
2,019	$ 10,364
2,020
Total payments	$ 452,967

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Related Party Transactions [Abstract]
Related party advances payable	$ 165,214	$ 131,505
Proceeds from related party advances	$ 33,709	$ 38,442

Stockholders' Equity (Details)

Stockholders' Equity (Details)	12 Months Ended
	Mar. 31, 2015USD ($)shares$ / shares	Mar. 31, 2014USD ($)$ / sharesshares	May. 29, 2015$ / sharesshares
Class of Stock [Line Items]
Common Stock, par value per share	$ 0.001	$ 0.001
Common Stock, shares authorized | shares	480,000,000	480,000,000
Preferred Stock, par value per share	$ 0.001	$ 0.001
Preferred Stock, shares authorized | shares	20,000,000	20,000,000
Potentially issuable shares upon the conversion of convertible notes payable and interest | shares	27,458,608
Amount Converted | $	$ 401,582	$ 446,109
Shares of Common Stock Issued | shares	113,585
Maximum [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share	$ 0.02
Minimum [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share	0.007
Average [Member]
Class of Stock [Line Items]
Debt instrument, conversion price per share	$ 0.01
Subsequent Event [Member]
Class of Stock [Line Items]
Common Stock, par value per share			$ 0.001
Common Stock, shares authorized | shares			480,000,000
Preferred Stock, par value per share			$ 0.001
Preferred Stock, shares authorized | shares			20,000,000

Commitments (Details)

Commitments (Details) - Mar. 31, 2015 - Office Space, Legal Services, Accounting Services, Fundraising and Management Services [Member] - USD ($)	Total
Other Commitments [Line Items]
Fees incurred in the period	$ 200,383
Commitments recorded as accounts payable and accrued expenses	$ 172,246

Business Segments (Details)

Business Segments (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
REVENUE	$ 128,133	$ 113,009
GROSS PROFIT	58,388	(219)
OPERATING EXPENSES	644,387	669,899
TOTAL ASSETS	11,328	77,745
Aquarium and Aquarium Supplies [Member]
Segment Reporting Information [Line Items]
REVENUE	128,133	113,009
GROSS PROFIT	58,388	(219)
OPERATING EXPENSES	103,091	144,788
TOTAL ASSETS	$ 6,800	$ 24,756
Medical Technology [Member]
Segment Reporting Information [Line Items]
REVENUE
GROSS PROFIT
OPERATING EXPENSES	$ 80,000	$ 85,000
TOTAL ASSETS
Corporate [Member]
Segment Reporting Information [Line Items]
REVENUE
GROSS PROFIT
OPERATING EXPENSES	$ 461,296	$ 440,111
TOTAL ASSETS	$ 4,528	$ 52,989

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income tax rate reconciliation:
Tax benefit at U.S. statutory rate	$ 337,000	$ 370,000
Amortization of discount on convertible notes payable	(136,000)	(160,000)
Valuation allowance	$ (201,000)	$ (210,000)
Income tax expense

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Jun. 06, 2015	May. 29, 2015	Mar. 31, 2015	Mar. 31, 2014
Subsequent Event [Line Items]
Conversion of convertible notes to common stock			$ 401,582	$ 446,109
Conversion of convertible notes and interest into common stock, shares			113,585
Subsequent Event [Member]
Subsequent Event [Line Items]
Reincorporation, date		May 29, 2015
Reincorporation, state		Nevada
Subsequent Event [Member] | Convertible Note Payable Dated December 31, 2014, Two [Member]
Subsequent Event [Line Items]
Date	Jun. 1, 2015
Debt instrument, face amount	$ 125,059
Conversion of convertible notes to common stock	$ 130,267
Conversion of convertible notes and interest into common stock, shares	6,513,344
Subsequent Event [Member] | Convertible Note Payable Dated June 30, 2014 [Member]
Subsequent Event [Line Items]
Date	Jun. 6, 2015
Debt instrument, face amount	$ 62,980
Conversion of convertible notes to common stock	$ 13,600
Conversion of convertible notes and interest into common stock, shares	680,000